Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Safety Study of Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

NCT03283917 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03283917
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03283917 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Safety Study of Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Completed
Start date
February 7, 2018
Completion date
June 17, 2026
Enrollment
21 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

newly diagnosed primary amyloidosis, recurrent primary amyloidosis, refractory primary amyloidosis